Iodine-131 treatment and chromosomal damage: In vivo dose-effect relationship

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 5, 2004, Pages 676-684

  Erselcan, Taner ^a   Sungu, Selma ^a   Ozdemir, Semra ^a   Turgut, Bulent ^a   Dogan, Derya ^a   Ozdemir, Ozturk ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Biological dosimetry; Chromosomal aberration; Iodine 131 treatment; Sister chromatid exchange; Thyroid cancer

Indexed keywords

IODINE 131;

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; MALE; PERIPHERAL LYMPHOCYTE; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOISOTOPE THERAPY; SISTER CHROMATID EXCHANGE; THYROID CANCER; THYROTOXICOSIS;

EID: 2442534780     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1427-3     Document Type: Article

References (42)

1. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37:606-612.
2. Dottorini ME. Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine. J Nucl Med 1996; 37:612-615.
3. 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002; 29:1581-1587.
4. 131I-lipiodol therapy. Eur J Nucl Med Mol Imaging 2003; 30:554-561.
5. 99mTc-HMPAO causes severe chromosomal aberrations in lymphocytes. J Nucl Med 2002; 43:203-206.
6. de Oliveira EM, Suzuki MF, do Nascimento PA, da Silva MA, Okazaki K. Evaluation of the effect of 90Sr beta-radiation on human blood cells by chromosome aberration and single cell gel electrophoresis (comet assay) analysis. Mutat Res 2001; 476:109-121.
7. Venkatachalam P, Solomon FD, Prabhu BK, Mohankumar MN, Gajendiran N, Jeevanram RK. Estimation of dose in cancer patients treated with fractionated radiotherapy using translocation, dicentrics and micronuclei frequency in peripheral blood lymphocytes. Mutat Res 1999; 429:1-12.
8. 131I therapy for thyroid cancer. Int J Radiat Biol 1996; 69:259-268.
9. Sonmez S, Ikbal M, Gepdiremen A, Oztas S. Sister chromatid exchange analysis in patients exposed to low dose of iodine-131 for thyroid scintigraphy. Mutat Res 1997; 393: 259-262.
10. Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, Futatsuya R, Michigishi T, Tonami N, Seto H, Goodwin DA. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. J Nucl Med 1998; 39:436-440.
11. 131I treatment in hyperthyroidism patients. Mutagenesis 1998; 13:95-98.
12. M'Kacher R, Schlumberger M, Legal JD, Violot D, Beron-Gaillard N, Gaussen A, Parmentier C. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. J Nucl Med 1998; 39:825-829.
13. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J Nucl Med 1999; 26:1589-1596.
14. Monsieurs MA, Thierens HM, van de Wiele CV, Vral AM, Meirlaen IA, de Winter HA, de Sadeleer CJ, de Ridder LI, Kaufman JM, Dierckx RA. Estimation of risk based on biological dosimetry for patients treated with radioiodine. Nucl Med Commun 1999; 20:911-917.
15. 131I. J Nucl Med 2000; 41:17-22.
16. Catena C, Conti D, Trenta G, Righi E, Breuer F, Melacrinis FF, Montesano T, Ventroni G, Ronga G. Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131-I therapy. J Nucl Med 2000; 41:1522-1524.
17. Ramirez MJ, Puerto S, Galofre P, Parry EM, Parry JM, Creus A, Marcos R, Surralles J. Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis 2000; 21:1581-1586.
18. Puerto S, Marcos R, Ramirez MJ, Galofre P, Creus A, Surralles J. Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. Mutat Res 2000; 469: 147-158.
19. Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, Migliore L, Barale R. Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res 2002; 514:77-85.
20. Livingston GK, Foster AE, Elson HR. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes. J Toxicol Environ Health 1993; 40:367-375.
21. Monteiro GO, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, Leonard A, Gerber G, Rueff J. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 2000; 15:69-75.
22. Lambert V, Thierens H, Monsieurs M, Roncancio C, Laurent C. Translocation frequencies measured in patients one year after radioactive iodine therapy for thyrotoxicosis. Int J Radiat Biol 2001; 77:679-685.
23. Fenech M. Biomarkers of genetic damage for cancer epidemiology. Toxicology 2002; 181-182:411-416.
24. Pauwels EK, Smit JW, Slats A, Bourguignon M, Overbeek F. Health effects of therapeutic use of I-131 in hyperthyroidism. Q J Nucl Med 2000; 44:333-339.
25. de Keizer B, Koppeschaar HP, Zelissen PM, Lips CJ, van Rijk PP, van Dijk A, de Klerk JM. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001; 28:198-202.
26. Freitas J. Therapeutic options in the management of toxic and nontoxic goiter. Semin Nucl Med 2000; 30:88-97.
27. Little JB. Cellular, molecular and carcinogenic effects of radiation. Hematol Oncol Clin North Am 1993; 7:337-352.
28. Peltenburg LTC. Radiosensitivity of tumor cells. Q J Nucl Med 2000; 44:355-363.
29. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS, Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997; 15:1455-1460.
30. Pouget JP, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med 2001; 28:541-561.
31. M'Kacher R, Legal JD, Schlumberger M, Aubert B, Beron-Gaillard N, Gaussen A, Parmentier C. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. J Nucl Med 1997; 38:377-380.
32. Rusov V, Zelentsova T, Melentchuk I, Beglaryan M. About some physical mechanisms of statistics of radiation-induced effects formation and non-linear cell response in low dose area. Radiat Meas 2001; 34:105-108.
33. Müller WU, Nusse M, Miller BM, Slavotinek A, Viaggi S, Streffer C. Micronuclei: a biological indicator of radiation damage. Mutat Res 1996; 366:163-169.
34. Streffer C, Muller WU, Kryscio A, Bocker W. Micronucleibiological indicator for retrospective dosimetry after exposure to ionizing radiation. Mutat Res 1998; 404:101-105.
35. Delic J, Magdelenat H, Barbaroux C, Chaillet MP, Dubray B, Gluckman E, Fourquet A, Girinsky T, Cosset JM. In vivo induction of apoptosis in human lymphocytes by therapeutic fractionated total body irradiation. Br J Radiol 1995; 68:997-1003.
36. Hertveldt K, Philippe J, Thierens H, Cornelissen M, Vral A, De Ridder L. Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis in vitro in human peripheral blood lymphocytes. Int J Radiat Biol 1997; 71:429-433.
37. Technical Report No. 405. Cytogenetic analysis for radiation dose assessment, a manual. Vienna: International Atomic Energy Agency, 2001.
38. Pillay M. Dosimetric aspects. In: Sampson CB, ed. Textbook of radiopharmacy: theory and practice, 3rd edn. The Netherlands: Gordon & Breach Science; 1999:447-460.
39. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. Low sensitivity of the sister chromatid exchange assay to detect the genotoxic effects of radioiodine therapy. Mutagenesis 1999; 14:221-226.
40. Bozkurt G, Yuksel M, Karabogaz G, Sut N, Savran FO, Palanduz S, Yigitbasi ON, Algunes C. Sister chromatid exchanges in lymphocytes of nuclear medicine physicians. Mutat Res 2003; 535:205-213.
41. Bilban-Jakopin C, Bilban M. Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease. Mutat Res 2001; 497:81-88.
42. Strom SS, Gu Y, Sigurdson AJ, Bailey NM, Amos CI, Spitz MR, Rodriguez MA, Liang JC. Chromosome breaks and sister chromatid exchange as predictors of second cancers in Hodgkin's disease. Leuk Lymphoma 1998; 28:561-566.